October 2023 Snap Recap: ODAC Decision Making and Breast Cancer News

News
Video

In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.

Halloween wasn’t the only event in October worth celebrating. In the October episode of Snap Recap, CancerNetwork® reviews key news items as decided on by our readers. This included articles on the effectiveness of reducing ctDNA tumor fractions with neoadjuvant chemotherapy in triple-negative breast cancer, the benefits of hypofractionated vs standard radiotherapy for breast cancer, the results of the October Oncologic Drug Advisory Committee (ODAC) meeting, the FDA awarding fast track designation to AVB-001 in ovarian cancer, and ongoing discussions from September’s Prostate Cancer Awareness Month.1-4

Full versions of the article are referenced below in the order that they appear in the show:

References

  1. Parsons HA, Blewett T, Chu X, et al. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. Ann Oncol. Published online August 18, 2023. doi:10.1016/j.annonc.2023.08.004
  2. Wong JS, Uno H, Tramontano A, et al. Patient-reported and toxicity results from the FABREC study: a multicenter randomized trial of hypofractionated vs. conventionally-fractionated postmastectomy radiation therapy after implant-based reconstruction. Presented at: 2023 American Society for Radiation Oncology Annual Meeting (ASTRO); October 1-4, 2023; San Diego, CA; abstract LBA05.
  3. Oncologic Drugs Advisory Committee (ODAC) Meeting. Streamed live October 5, 2023. Accessed October 5, 2023. https://bit.ly/3PMMRt9
  4. Avenge Bio receives FDA fast track designation for AVB-001, a novel cell therapy leveraging the LOCOcyte™ immunotherapy platform. News release. Avenge Bio, Inc. October 2, 2023. Accessed October 3, 2023. https://bit.ly/3rAwOq7

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Multidisciplinary collaboration may help in minimizing the treatment burden among patients with prostate cancer, according to Curtiland Deville Jr., MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Related Content
Patients with painful lesions who did not undergo treatment with opioids or reirradiation generally had better outcomes than those who did.

Classification System May Identify QOL Benefit with Palliative Radiotherapy

Roman Fabbricatore
April 18th 2025
Article

Patients with painful lesions who did not undergo treatment with opioids or reirradiation generally had better outcomes than those who did.

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

At baseline, 55% of patients achieved at least 6 metabolic equivalence tasks hours per week, 47% achieved it at timepoint 2, and 43% at timepoint 3.

Female AYA Cancer Survivors May Benefit From Increased Physical Activity

Ariana Pelosci
April 10th 2025
Article

The study found that older females with central nervous system tumors had significantly lower vigorous physical activity participation vs their counterparts.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Data from the LOXO-TRK-14001, SCOUT, and NAVIGATE trials support the full approval of larotrectinib in NTRK gene fusion-positive tumors.

FDA OKs Larotrectinib in Adult and Pediatric NTRK+ Tumor Populations

Russ Conroy
April 10th 2025
Article

Data from the LOXO-TRK-14001, SCOUT, and NAVIGATE trials support the full approval of larotrectinib in NTRK gene fusion-positive tumors.

Auditory Attention Decay Noted Post-Treatment in Pediatric Cerebellar Tumors

Auditory Attention Decay Noted Post-Treatment in Pediatric Cerebellar Tumors

Ariana Pelosci
April 9th 2025
Article

Quality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric patients with cerebellar tumors.